GluGene Therapeutics aspires to be a trusted strategic partner for global biotech and pharmaceutical companies in the field of AAV-based gene therapy vector development.

Through our proprietary platform combining directed evolution with AI-based virtual screening, we precisely design target cell- and tissue-specific AAV vectors and establish scalable mass production systems considering clinical and commercial applications. This enables us to provide gene therapy solutions that safely and efficiently target cells and organs that were difficult to access with conventional technologies.

GluGene Therapeutics‘ technological capabilities are continuously validated through proven collaborative research and partnership outcomes with domestic and international research institutions and companies, expanding into core partnership capabilities that accelerate next-generation gene therapy development.